Professional Affiliation and Role
Dorian Magee is currently associated with Korro Bio, a biotechnology company focused on developing novel genetic medicines by editing RNA to modulate biological pathways. While direct confirmation of Magee’s formal title or specific responsibilities at Korro Bio is unavailable, the connection to Korro Bio is established without conflicting data indicating otherwise. Notably, LinkedIn profiles and external references predominantly associate a Dorian Magee with Apogee Therapeutics in the Greater Boston area; however, those details appear separate from the Korro Bio affiliation.
Educational Background
Dorian Magee is an alumnus of the Florida Institute of Technology, graduating in 2014. This institution, noted for its focus on STEM, suggests Magee’s foundation is likely in a technical or scientific field. Supporting evidence from a 2017 Florida Tech alumni publication references Magee in the context of the university community, but no advancement degrees or specific research projects are detailed.
Korro Bio Company Overview (Context Relevant to Magee)
Korro Bio is a Cambridge, Massachusetts–based biotechnology company specializing in precise genetic medicines using a proprietary platform named Oligonucleotide Promoted Editing of RNA (OPERA®). The company targets complex prevalent diseases such as alpha-1 antitrypsin deficiency (AATD), aiming to edit single-letter mutations in RNA to restore or modulate protein function. Korro Bio has secured Orphan Drug Designation from the European Medicines Agency for its therapeutic program KRRO-110 and has publicly reported financial results for Q1 and Q2 of 2025, indicating active clinical and commercial development progress. The company recently appointed Loïc Vincent, Ph.D., as Chief Scientific Officer, highlighting a period of strategic growth.
Corporate Location and Contact Information
Korro Bio is headquartered at:
- 60 First Street, 2nd Floor, Suite 250, Cambridge, MA 02141
Their corporate communications channels categorize inquiries by investor relations, human resources, general, and media relations, but no direct contact details linked to Magee were found.
Industry and Scientific Relevance
While Magee’s individual contributions, responsibilities, and major achievements at Korro Bio are not publicly detailed, the company’s cutting-edge RNA editing approach places its staff and leadership in a highly specialized biotech domain. Key sales-relevant insights include Korro’s focus on rare genetic diseases, advanced RNA therapeutics, and progress through regulatory milestones—all indicative of a company in clinical development and growth phases.
Summary of Relevant Data
- Name: Dorian Magee
- Company: Korro Bio (Confirmed association; no conflicting company affiliation relevant to Korro)
- Location (Company HQ): Cambridge, MA
- Education: Florida Institute of Technology, Class of 2014
- Professional Network: Over 500 connections noted on LinkedIn profile related to Apogee Therapeutics (potentially the same professional, but Korro Bio affiliation separate)
- Korro Bio Business Focus: RNA editing medicines for genetic diseases using OPERA® platform, with emphasis on alpha-1 antitrypsin deficiency and other complex diseases
- Recent Company Milestones: European Orphan Drug Designation (KRRO-110), appointment of Chief Scientific Officer, Q1 and Q2 2025 financial disclosures
- Publicly Available Roles/Contributions of Magee at Korro: Not found in open sources; LinkedIn profile shows experience at Apogee Therapeutics but no data specifying Korro Bio role or achievements
This profile emphasizes Dorian Magee’s educational foundation, confirmed association with Korro Bio, and the innovative scientific framework of the company, which together suggest a candidate knowledgeable in RNA-based biotech therapeutics in a company advancing toward clinical and regulatory milestones. No direct role specifics or professional contributions were publicly available to delineate further responsibilities or decision-making authority within Korro Bio.
